1 - 25 of 49 results for author:"Fletcher J.A." in Literature citations
Results Customize
› Repeat search in UniProtKB (26)
| Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Lee C.H., Ali R.H., Rouzbahman M., Marino-Enriquez A., Zhu M., Guo X., Brunner A.L., Chiang S., Leung S., Nelnyk N. et al. Am. J. Surg. Pathol. 36:1562-1570(2012) · Mapped (10) |
| The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Lee C.H., Marino-Enriquez A., Ou W., Zhu M., Ali R.H., Chiang S., Amant F., Gilks C.B., van de Rijn M., Oliva E. et al. Am. J. Surg. Pathol. 36:641-653(2012) · Mapped (5) |
| Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Edris B., Weiskopf K., Volkmer A.K., Volkmer J.P., Willingham S.B., Contreras-Trujillo H., Liu J., Majeti R., West R.B., Fletcher J.A. et al. Proc. Natl. Acad. Sci. U.S.A. 109:6656-6661(2012) · Mapped (5) |
| ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. Edris B., Espinosa I., Muhlenberg T., Mikels A., Lee C.H., Steigen S.E., Zhu S., Montgomery K.D., Lazar A.J., Lev D. et al. J. Pathol. 227:223-233(2012) · Mapped (3) |
| The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. Wu X., Zhu M., Fletcher J.A., Giobbie-Hurder A., Hodi F.S. PLoS ONE 7:e29622-e29622(2012) · UniProtKB (3) |
| 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Lee C.H., Ou W.B., Marino-Enriquez A., Zhu M., Mayeda M., Wang Y., Guo X., Brunner A.L., Amant F., French C.A. et al. Proc. Natl. Acad. Sci. U.S.A. 109:929-934(2012) · UniProtKB (2) · Mapped (5) |
| Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Janeway K.A., Kim S.Y., Lodish M., Nose V., Rustin P., Gaal J., Dahia P.L., Liegl B., Ball E.R., Raygada M. et al. Proc. Natl. Acad. Sci. U.S.A. 108:314-318(2011) · Mapped (3) |
| AXL regulates mesothelioma proliferation and invasiveness. Ou W.B., Corson J.M., Flynn D.L., Lu W.P., Wise S.C., Bueno R., Sugarbaker D.J., Fletcher J.A. Oncogene 30:1643-1652(2011) · Mapped (2) |
| ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Chi P., Chen Y., Zhang L., Guo X., Wongvipat J., Shamu T., Fletcher J.A., Dewell S., Maki R.G., Zheng D. et al. Nature 467:849-853(2010) · Mapped (14) |
| Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Rossi S., Gasparotto D., Toffolatti L., Pastrello C., Gallina G., Marzotto A., Sartor C., Barbareschi M., Cantaloni C., Messerini L. et al. Am. J. Surg. Pathol. 34:1480-1491(2010) · Mapped (8) |
| Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Weisberg E., Choi H.G., Ray A., Barrett R., Zhang J., Sim T., Zhou W., Seeliger M., Cameron M., Azam M. et al. Blood 115:4206-4216(2010) · Mapped (1) |
| Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Parkkila S., Lasota J., Fletcher J.A., Ou W.B., Kivela A.J., Nuorva K., Parkkila A.K., Ollikainen J., Sly W.S., Waheed A. et al. Mod. Pathol. 23:743-750(2010) · Mapped (2) |
| Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Sadow P.M., Heinrich M.C., Corless C.L., Fletcher J.A., Nose V. Endocr. Pathol. 21:73-79(2010) · Mapped (35) |
| Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma. Yen C.C., Chen W.M., Chen T.H., Chen W.Y., Chen P.C., Chiou H.J., Hung G.Y., Wu H.T., Wei C.J., Shiau C.Y. et al. Int. J. Oncol. 35:775-788(2009) · Mapped (3) |
| Imatinib targeting of KIT-mutant oncoprotein in melanoma. Jiang X., Zhou J., Yuen N.K., Corless C.L., Heinrich M.C., Fletcher J.A., Demetri G.D., Widlund H.R., Fisher D.E., Hodi F.S. Clin. Cancer Res. 14:7726-7732(2008) · Mapped (7) |
| Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Heinrich M.C., Maki R.G., Corless C.L., Antonescu C.R., Harlow A., Griffith D., Town A., McKinley A., Ou W.B., Fletcher J.A. et al. J. Clin. Oncol. 26:5352-5359(2008) · Mapped (8) |
| Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Heinrich M.C., Owzar K., Corless C.L., Hollis D., Borden E.C., Fletcher C.D., Ryan C.W., von Mehren M., Blanke C.D., Rankin C. et al. J. Clin. Oncol. 26:5360-5367(2008) · Mapped (7) |
| Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies. French C.A., Fletcher J.A., Cibas E.S., Caulfield C., Allard P., Kroll T.G. Endocr. Pathol. 19:166-174(2008) · Mapped (9) |
| Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Ou W.B., Zhu M.J., Demetri G.D., Fletcher C.D., Fletcher J.A. Oncogene 27:5624-5634(2008) · Mapped (9) |
| BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. French C.A., Ramirez C.L., Kolmakova J., Hickman T.T., Cameron M.J., Thyne M.E., Kutok J.L., Toretsky J.A., Tadavarthy A.K., Kees U.R. et al. |
| Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Janeway K.A., Liegl B., Harlow A., Le C., Perez-Atayde A., Kozakewich H., Corless C.L., Heinrich M.C., Fletcher J.A. Cancer Res. 67:9084-9088(2007) · Mapped (7) |
| BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Schmidt J., Derr V., Heinrich M.C., Crum C.P., Fletcher J.A., Corless C.L., Nose V. Am. J. Surg. Pathol. 31:1337-1343(2007) · Mapped (3) |
| KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Bauer S., Duensing A., Demetri G.D., Fletcher J.A. Oncogene 26:7560-7568(2007) · Mapped (12) |
| Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Davis I.J., Kim J.J., Ozsolak F., Widlund H.R., Rozenblatt-Rosen O., Granter S.R., Du J., Fletcher J.A., Denny C.T., Lessnick S.L. et al. Cancer Cell 9:473-484(2006) · Mapped (10) |
| Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oliveira A.M., Perez-Atayde A.R., Dal Cin P., Gebhardt M.C., Chen C.J., Neff J.R., Demetri G.D., Rosenberg A.E., Bridge J.A., Fletcher J.A. Oncogene 24:3419-3426(2005) · UniProtKB (1) |